Respiratory Syncytial Virus Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Sanofi, AstraZeneca, Pfizer, GlaxoSmithKline, Bavarian Nordic, Janssen

Posted on
by

Respiratory Syncytial Virus Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Sanofi, AstraZeneca, Pfizer, GlaxoSmithKline, Bavarian Nordic, Janssen
“Respiratory Syncytial Virus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Respiratory Syncytial Virus, historical and forecasted epidemiology as well as the Respiratory Syncytial Virus market trends in the 7MM.

DelveInsight’s “Respiratory Syncytial Virus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Respiratory Syncytial Virus, historical and forecasted epidemiology as well as the Respiratory Syncytial Virus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Respiratory Syncytial Virus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Respiratory Syncytial Virus Market Forecast

 

Some of the key facts of the Respiratory Syncytial Virus Market Report: 

  • The Respiratory Syncytial Virus market size was valued approximately USD 1,200 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2022, the total new cases of RSV (Respiratory Syncytial Virus) observed in the seven major markets (7MM) were approximately 8,495,000, projected to rise by the year 2032.
  • In 2022, within the EU4 nations, Germany reported the highest count of new RSV cases, approximately 533,000 cases, constituting about 6% of the overall cases across the seven major markets (7MM).
  • In 2022, Japan reported approximately 983,000 new cases of RSV, with expectations of an increase by 2032.
  • In 2022, the severity of RSV infection in adults in the US showed that 70% accounted for mild cases, 27% for moderate cases, and 3% for severe cases among the total incident cases of RSV.
  • Key Respiratory Syncytial Virus Companies: Sanofi/ AstraZeneca, Pfizer, GlaxoSmithKline, Bavarian Nordic, Janssen Research, Moderna, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, Alnylam Pharmaceuticals, and others
  • Key Respiratory Syncytial Virus Therapies: Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others
  • The Respiratory Syncytial Virus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Respiratory Syncytial Virus pipeline products will significantly revolutionize the Respiratory Syncytial Virus market dynamics.

 

Respiratory Syncytial Virus Overview

A common respiratory virus that affects the nose, throat, lungs, and breathing passages is called the respiratory syncytial virus (RSV). Within the family Pneumoviridae and order Mononegavirales, RSV is classified as a member of the genus Orthopneumovirus.

 

Get a Free sample for the Respiratory Syncytial Virus Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market

 

Respiratory Syncytial Virus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Respiratory Syncytial Virus Epidemiology Segmentation:

The Respiratory Syncytial Virus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Respiratory Syncytial Virus
  • Prevalent Cases of Respiratory Syncytial Virus by severity
  • Gender-specific Prevalence of Respiratory Syncytial Virus
  • Diagnosed Cases of Episodic and Chronic Respiratory Syncytial Virus

 

Download the report to understand which factors are driving Respiratory Syncytial Virus epidemiology trends @ Respiratory Syncytial Virus Epidemiology Forecast

 

Respiratory Syncytial Virus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Respiratory Syncytial Virus market or expected to get launched during the study period. The analysis covers Respiratory Syncytial Virus market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Respiratory Syncytial Virus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Respiratory Syncytial Virus Therapies and Key Companies

  • Nirsevimab: Sanofi/ AstraZeneca
  • RSVpreF Vaccine: Pfizer
  • RSVpreF3 Vaccine: GlaxoSmithKline
  • MVA-BN RSV Vaccine: Bavarian Nordic
  • Ad26.RSV.pre F Vaccine: Janssen
  • mRNA-1345 Vaccine: Moderna
  • NJ-53718678: Janssen Research & Development
  • Clesrovimab: Merck Sharp & Dohme LLC
  • EDP-938: Enanta Pharmaceuticals
  • MEDI8897: AstraZeneca
  • GS-5806: Gilead Sciences
  • RV521: Pfizer
  • ALN-RSV01: Alnylam Pharmaceuticals

 

Discover more about therapies set to grab major Respiratory Syncytial Virus market share @ Respiratory Syncytial Virus Treatment Landscape

 

Respiratory Syncytial Virus Market Strengths

  • The successful trials of upcoming vaccines namely, RSVPref3, mRNA1345, and RSVPref have displayed the opportunity to change the treatment pattern mainly in the high risk patients i.e. elderly, infants and pregnant women. Further, the approval of these vaccines will proliferate the growth of the overall RSV market.
  • RSV infection can now be identified quickly due to advances in molecular diagnostics. A new taxonomic nomenclature for RSV was recently accepted, while diagnostic and omics approaches have revealed novel modalities for early detection of RSV infections and better knowledge of disease pathogenesis

 

Respiratory Syncytial Virus Market Opportunities

  • RSV highlights the urgent need to develop more cost-effective antiviral preventive strategies, in order to decrease the burden of RSV infections requiring hospitalizations.
  • Data gaps in the disease burden need to be addressed to understand the epidemiology. Understanding these variances will be critical to establishing cost-effective interventions.
  • Combining RSV shots with other vaccines like influenza and COVID19 has the potential to offer a comprehensive and more efficient defense against various respiratory viruses.

 

Scope of the Respiratory Syncytial Virus Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Respiratory Syncytial Virus Companies: Sanofi/ AstraZeneca, Pfizer, GlaxoSmithKline, Bavarian Nordic, Janssen Research, Moderna, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, Alnylam Pharmaceuticals, and others
  • Key Respiratory Syncytial Virus Therapies: Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others
  • Respiratory Syncytial Virus Therapeutic Assessment: Respiratory Syncytial Virus current marketed and Respiratory Syncytial Virus emerging therapies
  • Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus market drivers and Respiratory Syncytial Virus market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Respiratory Syncytial Virus Unmet Needs, KOL’s views, Analyst’s views, Respiratory Syncytial Virus Market Access and Reimbursement  

 

To know more about Respiratory Syncytial Virus companies working in the treatment market, visit @ Respiratory Syncytial Virus Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Respiratory Syncytial Virus Market Report Introduction

2. Executive Summary for Respiratory Syncytial Virus

3. SWOT analysis of Respiratory Syncytial Virus

4. Respiratory Syncytial Virus Patient Share (%) Overview at a Glance

5. Respiratory Syncytial Virus Market Overview at a Glance

6. Respiratory Syncytial Virus Disease Background and Overview

7. Respiratory Syncytial Virus Epidemiology and Patient Population

8. Country-Specific Patient Population of Respiratory Syncytial Virus 

9. Respiratory Syncytial Virus Current Treatment and Medical Practices

10. Respiratory Syncytial Virus Unmet Needs

11. Respiratory Syncytial Virus Emerging Therapies

12. Respiratory Syncytial Virus Market Outlook

13. Country-Wise Respiratory Syncytial Virus Market Analysis (2019–2032)

14. Respiratory Syncytial Virus Market Access and Reimbursement of Therapies

15. Respiratory Syncytial Virus Market Drivers

16. Respiratory Syncytial Virus Market Barriers

17.  Respiratory Syncytial Virus Appendix

18. Respiratory Syncytial Virus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services